Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P338. Ready to Go and Let Go: Perspectives on transition and transfer from paediatric to adult health care: A paired pilot survey of adolescent IBD patients and their parents
P338. The safety of laparoscopy in complex Crohn's disease
Authors:

N. Dimitriou1, P. Morar1, J. Warusavitarne1, 1St Mark's Hospital, Colorectal, London, United Kingdom

P338

Serologic profile and reactivation of Hepatitis B in rheumatic and Inflammatory Bowel Disease patients treated with TNF inhibitors bowel disease

Authors:

S. Vitor1, L. Meireles1, V. Romão2, C. Freitas1, S. Fernandes*, M.J. Gonçalves2, L. Correia1, M.J. Savedra2, H. Canhão2, J. Fonseca2, J.A. Pereira da Silva2, J. Velosa1

1Hospital Santa Maria, Gastroenterology and Hepatology, Lisbon, Portugal, 2Hospital Santa Maria, Rheumatology, Lisbon, Portugal

P339.

Surgical treatment of female genital fistula in Crohn's disease

Authors:

L. Franceschilli, I. Capuano, G. Milito, F. Giorgi, A. Gaspari, P. Sileri, University of Rome Tor Vergata, Department of Sperimental medicine and Surgery, Rome, Italy

P339. An audit of IBD care: Are we up to standards? A patients perspective
P339. Epidemiological study of inflammatory bowel disease in single tertiary centre – First report from Serbia
P339. The routine measurement of thiopurine metabolite levels results in dose optimisation in one third of IBD patients; results from a district general hospital
Authors:

H. Dewhurst1, H. Johnson2, J. Begley3, S. Weaver2, S. McLaughlin2, 1Royal Bournemouth Hospital, Gastroenterology Research, Bournemouth, United Kingdom, 2Royal Bournemouth Hospital, Gastroenterology, Bournemouth, United Kingdom, 3Royal Bournemouth Hospital, Clinical Biochemistry, Bournemouth, United Kingdom

P339

High dose intravenous iron isomaltoside 1000 in subjects with inflammatory bowel disease - the PROMISE trial

Authors:

J.F. Dahlerup*1, S. Lindgren2

1Aarhus University Hospital, Department of Hepatology and Gastroenterology , Aarhus, Denmark, 2Lund University, University Hospital MAS, Department of gastroenterology, Malmö, Sweden

P340.

Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease – the McGill experience

Authors:

U. Kopylov1, W. Afif2, A. Cohen3, A. Bitton1, G. Wild1, T. Bessissow1, J. Wyse3, T. Al-Taweel1, A. Szilagy3, E.G. Seidman1, 1McGill University Health Center, Gastroenterology, Montreal, Canada, 2McGill University, Division of Gastroenterology, Montreal Quebec, Canada, 3Jewish General Hospital, Department of Gastroenterology, Montreal, Canada

P340. Differences in demographic data and disease extension in patients with ulcerative colitis associated with primary sclerosing cholangitis
P340. Has the risk of developing colorectal cancer in patients with ulcerative colitis been overstated? A meta-analysis
P340. Therapy of intestinal fistula with autologous adipose tissue derived stem cells doesn't lead to fistula closure in animal model – first results
Authors:

O. Ryska1, Z. Serclova1, O. Mestak2, E. Matouskova3, P. Vesely2, 1Central Military Hospital, Department of Surgery, Prague 6, Czech Republic, 2Bulovka Hospital, Department of Plastic Surgery, Prague 8, Czech Republic, 33rd Medical Faculty Charles University, Department of Burns Medicine, Prague 10, Czech Republic

P340

Adalimumab treatment in Ulcerative Colitis patients who are naïve to anti-TNF: Week 8 of our pilot study

Authors:

C. Muñoz Villafranca*1, R. Higuera2, O. Merino3, Ó. Nantes4, P. Ramirez de la Piscina5, A. Munagorri6, C. Rodriguez4, P. Arreba7, M.A. Ogueta8, J.A. Arévalo9, A. Bernal9, L. Gómez3, S. Ibañez10, J. Ortiz de Zárate11, J.L. Cabriada9

1Hospital Universitario de Basurto, Aparato Digestivo, Bilbao, Spain, 2Hospital San Eloy, Gastroenterlogy, Baracaldo, Spain, 3Hospital Universitario de Cruces, Gastroenterology, Baracaldo, Spain, 4Hospital de Navarra, Gastroenterology, Pamplona, Spain, 5Hospital de Txagorritxu, Gastroenterology, Vitoria, Spain, 6Hospital Donostia, Gastroenterology, Donosti, Spain, 7Hospital Universitario de Basurto, Gastroenterology, Bilbao, Spain, 8Hospital de Santiago, Gastroenterology, Vitoria, Spain, 9Hospital de Galdácano, Gastroenterology, Galdácano, Spain, 10Hospital universitario de Cruces, Gastroenterology, Baracaldo, Spain, 11Hospital Universitario de Basurto, Gastroenterology, Bilbao, Spain

P341.

Steroids may reduce the benefit of exclusive enteral feeding in paediatric Crohn's disease

Authors:

J.-P. Gonçalves, L. Quaresma, H. Rego, A. Ratola, M. Tavares, E. Trindade, J. Amil, Hospital S. João, Department of Pediatric Gastroenterology Hepatology & Nutrition, Porto, Portugal

P341. A trial with mercaptopurine following azathioprine intolerance is a safe treatment strategy for the majority of patients with IBD
P341. Association of hygienic factors and inflammatory bowel disease in Rio de Janeiro, Brazil
P341. Therapeutic depletion of myeloid lineage leucocytes in ulcerative colitis patients instead of pharmacological intervention: clinical and endoscopic features of responders and non-responders
Authors:

T. Tanaka1, H. Goishi1, S. Sugiyama1, H. Yamada1, 1Akitsu Prefectural Hospital, Hiroshima, Japan

P341

Endoscopy Assessment at 1-year Identifies Long-term Responders to Thiopurines Maintenance Therapy in Patients with Crohn's Disease

Authors:

Y. Qiu, R. Mao, B.-l. Chen, Y. He, Z.-r. Zeng, M.-h. Chen*

First Affiliated Hospital of Sun Yat-Sen University, Department of Gastroenterology, Guangzhou, China

P342.

Splitting the normal daily dose of thioguanine may be efficacious treatment for IBD and avoid hepatic toxicity

Authors:

P. Pavlidis1, A. Ansari1, J. Duley2, I. Oancea3, T. Florin4, 1Surrey and Sussex Healthcare NHS Trust, East Surrey Hospital, Redhill, Department for Digestive Diseases, Red Hill, United Kingdom, 2University of Queensland, Department of Pharmacy, Woollloongabba, Australia, 3University of Queensland, Translational Research Institute, Immunity, Infection, and Inflammation Program, Mater Research Institute, Woolloongabba, Australia, 4Mater Research Institute – UQ, Gastroenterology, South Brisbane, Australia

P342. Adalimumab prevents post-operative Crohn's disease recurrence, and is superior to thiopurines: Early results from the prospective POCER study